目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 GLOBAL MARKET SIZE ESTIMATION, 2024
2.2.2 SEGMENTAL MARKET ASSESSMENT
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY
3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS IN LIGASE ENZYMES MARKET
3.3 DISRUPTIVE TRENDS SHAPING LIGASE ENZYMES MARKET
3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS

4 PREMIUM INSIGHTS
4.1 GLOBAL LIGASE ENZYMES MARKET SNAPSHOT
4.2 NORTH AMERICA: LIGASE ENZYMES MARKET, BY TYPE AND COUNTRY (2024)
4.3 LIGASE ENZYMES MARKET, BY TYPE (2024)
4.4 LIGASE ENZYMES MARKET, BY END USER (2024)
4.5 LIGASE ENZYMES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.6 UNMET NEEDS & WHITE SPACES
4.7 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
4.7.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
4.9 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising genomics & NGS activity
5.2.1.2 Growth of molecular diagnostics & personalized medicine
5.2.1.3 Growing use in synthetic biology
5.2.2 RESTRAINTS
5.2.2.1 Dependence on research funding
5.2.3 OPPORTUNITIES
5.2.3.1 Development of thermostable/performance-engineered ligases
5.2.3.2 Development of lyophilized/shelf-stable ligases for point-of- care testing (POCT) and low-resource markets
5.2.4 CHALLENGES
5.2.4.1 Batch-to-batch variability & quality control
5.2.4.2 Growth in adoption of sequence and ligase-independent cloning (SLIC)

6 INDUSTRY TRENDS
6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
6.1.1 SHIFT TOWARD HIGH-THROUGHPUT & AUTOMATED WORKFLOWS
6.1.2 EXPANSION OF LIGASE APPLICATIONS IN RAPID & POINT-OF-CARE TESTING
6.2 VALUE CHAIN ANALYSIS
6.3 ECOSYSTEM ANALYSIS
6.4 TECHNOLOGY ANALYSIS
6.4.1 KEY TECHNOLOGIES
6.4.1.1 Precision fermentation
6.4.1.2 Enzyme engineering & protein design
6.4.2 COMPLEMENTARY TECHNOLOGIES
6.4.2.1 Chromatography & purification technologies
6.4.2.2 Cryopreservation & stabilization technologies
6.5 PATENT ANALYSIS
6.5.1 METHODOLOGY
6.5.2 PATENTS APPLIED & GRANTED, 2014-2024
6.6 TRADE ANALYSIS
6.6.1 IMPORT DATA (HS CODE 350790)
6.6.2 EXPORT DATA (HS CODE 350790)
6.7 PORTER'S FIVE FORCES ANALYSIS
6.7.1 THREAT OF NEW ENTRANTS
6.7.2 THREAT OF SUBSTITUTES
6.7.3 BARGAINING POWER OF SUPPLIERS
6.7.4 BARGAINING POWER OF BUYERS
6.7.5 INTENSITY OF COMPETITIVE RIVALRY
6.8 TARIFF & REGULATORY LANDSCAPE
6.8.1 TARIFF DATA (HS CODE 350790)
6.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
6.8.3 REGULATORY FRAMEWORK
6.9 PRICING ANALYSIS
6.9.1 AVERAGE SELLING PRICE TREND OF LIGASE ENZYMES, BY KEY PLAYER, 2022-2024
6.9.2 AVERAGE SELLING PRICE OF LIGASE ENZYMES, BY REGION, 2024
6.10 KEY CONFERENCES & EVENTS, 2025-2026
6.11 KEY STAKEHOLDERS & BUYING CRITERIA
6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
6.11.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS
6.11.3 BUYING CRITERIA
6.12 INVESTMENT & FUNDING SCENARIO
6.13 IMPACT OF AI/GENERATIVE AI ON LIGASE ENZYMES MARKET
6.13.1 AI USE CASES
6.13.2 KEY COMPANIES IMPLEMENTING AI
6.13.3 FUTURE OF AI
6.14 IMPACT OF 2025 US TARIFFS ON LIGASE ENZYMES MARKET
6.14.1 INTRODUCTION
6.14.2 KEY TARIFF RATES
6.14.3 PRICE IMPACT ANALYSIS
6.14.4 IMPACT ON COUNTRY/REGION
6.14.4.1 US
6.14.4.2 Europe
6.14.4.3 Asia Pacific
6.14.5 END-USE INDUSTRY IMPACT
6.14.5.1 Pharmaceutical & biotechnology companies
6.14.5.2 Medical device companies
6.14.5.3 Academic & research institutes
6.14.5.4 Hospitals & diagnostic laboratories

7 LIGASE ENZYMES MARKET, BY TYPE
7.1 INTRODUCTION
7.2 DNA LIGASES
7.2.1 HIGH ADOPTION OF DNA LIGASES TO SUPPORT MARKET GROWTH
7.3 RNA LIGASES
7.3.1 GROWING ADOPTION OF RNA SEQUENCING AND DEVELOPMENT IN RNA THERAPEUTICS TO DRIVE MARKET GROWTH
7.4 OTHER LIGASES

8 LIGASE ENZYMES MARKET, BY SOURCE
8.1 INTRODUCTION
8.2 VIRAL LIGASES
8.2.1 WIDE COMMERCIAL USE OF VIRAL LIGASES BY COMPANIES TO SUPPORT MARKET GROWTH
8.3 BACTERIAL LIGASES
8.3.1 HIGH SPECIFICITY AND COMPATIBILITY OF BACTERIAL LIGASES WITH CERTAIN APPLICATIONS TO SUPPORT MARKET GROWTH
8.4 EUKARYOTIC LIGASES
8.4.1 EXPANDING ROLE OF EUKARYOTIC LIGASES IN DNA REPAIR ASSAYS AND CRISPR-MEDIATED GENOME EDITING TO BOOST MARKET
8.5 ARCHAEAL LIGASES
8.5.1 RISING DEMAND FOR HIGH-TEMPERATURE LIGATION METHODS IN PCR CLONING TO FUEL GROWTH

9 LIGASE ENZYMES MARKET, BY GRADE
9.1 INTRODUCTION
9.2 RUO-GRADE LIGASES
9.2.1 LOW COST OF RUO-GRADE LIGASE ENZYMES TO SUPPORT MARKET GROWTH
9.3 GMP-GRADE LIGASES
9.3.1 GROWING PIPELINE FOR DNA AND RNA-BASED THERAPEUTICS TO SUPPORT MARKET GROWTH
9.4 DIAGNOSTIC-GRADE LIGASES
9.4.1 CONTINUOUS PRODUCT INNOVATION TO POSITION DIAGNOSTIC-GRADE LIGASES AS HIGH-OPPORTUNITY GROWTH SEGMENT

10 LIGASE ENZYMES MARKET, BY MOLECULAR BIOLOGY WORKFLOW
10.1 INTRODUCTION
10.2 CLONING & MUTAGENESIS
10.2.1 WIDE ADOPTION OF CLONING TECHNIQUES TO SUPPORT MARKET GROWTH
10.3 SYNTHETIC BIOLOGY
10.3.1 GROWING EXPANSION OF SYNTHETIC BIOLOGY IN HEALTHCARE TO DRIVE MARKET GROWTH
10.4 SEQUENCING
10.4.1 INCREASING DEMAND FOR LARGE-SCALE GENOME PROJECTS TO BOOST MARKET GROWTH
10.5 NUCLEIC ACID AMPLIFICATION
10.5.1 GROWING DEMAND FOR RAPID, ACCURATE, AND COST-EFFECTIVE MOLECULAR DIAGNOSTICS TO SUPPORT MARKET GROWTH

11 LIGASE ENZYMES MARKET, BY APPLICATION
11.1 INTRODUCTION
11.2 RESEARCH APPLICATIONS
11.2.1 GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH
11.3 DIAGNOSTIC APPLICATIONS
11.3.1 GROWING DEMAND FOR MOLECULAR DIAGNOSTICS AND PERSONALIZED MEDICINE TO SUPPORT MARKET GROWTH
11.4 THERAPEUTIC DEVELOPMENT & MANUFACTURING
11.4.1 GROWING DEMAND FOR GMP-GRADE ENZYMES IN LARGE-SCALE MANUFACTURING TO PROPEL MARKET GROWTH
11.5 OTHER APPLICATIONS

12 LIGASE ENZYMES MARKET, BY END USER
12.1 INTRODUCTION
12.2 ACADEMIC & RESEARCH INSTITUTES
12.2.1 GROWING RESEARCH STUDIES TO SUPPORT MARKET GROWTH
12.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
12.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE TO BOOST MARKET GROWTH
12.4 HOSPITALS & DIAGNOSTIC LABORATORIES
12.4.1 GROWING INTEGRATION OF LIGASE-BASED MOLECULAR DIAGNOSTIC TESTS INTO ROUTINE CARE TO SUPPORT MARKET GROWTH
12.5 MEDICAL DEVICE COMPANIES
12.5.1 GROWING FOCUS ON RAPID, RELIABLE, AND USER-FRIENDLY DIAGNOSTIC DEVICES TO FUEL GROWTH

13 LIGASE ENZYMES MARKET, BY REGION
13.1 INTRODUCTION
13.2 NORTH AMERICA
13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
13.2.2 US
13.2.2.1 Increasing R&D investments and funding to drive market
13.2.3 CANADA
13.2.3.1 Supportive government policies to propel market growth
13.3 EUROPE
13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
13.3.2 GERMANY
13.3.2.1 Strong healthcare infrastructure and government-backed genomics initiatives to support market
13.3.3 UK
13.3.3.1 Growing adoption of genomics and presence of advanced research infrastructure to drive demand
13.3.4 FRANCE
13.3.4.1 Growing government funding for R&D to propel market
13.3.5 ITALY
13.3.5.1 Growing research funding to drive market growth
13.3.6 SPAIN
13.3.6.1 Increasing number of biotechnology companies to drive demand
13.3.7 REST OF EUROPE
13.4 ASIA PACIFIC
13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
13.4.2 CHINA
13.4.2.1 Increasing R&D expenditure to support market growth
13.4.3 JAPAN
13.4.3.1 Advanced biotechnology industry and strong research base to support market growth
13.4.4 INDIA
13.4.4.1 Growing government support in evolving biotechnology sector to boost market
13.4.5 SOUTH KOREA
13.4.5.1 Increasing government support to boost market
13.4.6 AUSTRALIA
13.4.6.1 Growing biotechnology sector to boost demand
13.4.7 REST OF ASIA PACIFIC
13.5 LATIN AMERICA
13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
13.5.2 BRAZIL
13.5.2.1 Rising focus on biotechnology industry to support market
13.5.3 MEXICO
13.5.3.1 Government support for biopharmaceutical production to drive market
13.5.4 REST OF LATIN AMERICA
13.6 MIDDLE EAST
13.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST
13.6.2 GCC COUNTRIES
13.6.2.1 Saudi Arabia
13.6.2.1.1 Increasing investments in genomics to drive market
13.6.2.2 United Arab Emirates
13.6.2.2.1 Advancements in biopharmaceutical sector to drive demand
13.6.2.3 Rest of GCC Countries
13.6.3 REST OF MIDDLE EAST
13.7 AFRICA
13.7.1 GROWING FUNDING FOR SUPPORTING RESEARCH INFRASTRUCTURE TO DRIVE MARKET
13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW
14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
14.3 REVENUE ANALYSIS, 2020-2024
14.4 MARKET SHARE ANALYSIS, 2024
14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
14.5.1 STARS
14.5.2 EMERGING LEADERS
14.5.3 PERVASIVE PLAYERS
14.5.4 PARTICIPANTS
14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
14.5.5.1 Company footprint
14.5.5.2 Region footprint
14.5.5.3 Type footprint
14.5.5.4 Source footprint
14.5.5.5 Application footprint
14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
14.6.1 PROGRESSIVE COMPANIES
14.6.2 RESPONSIVE COMPANIES
14.6.3 DYNAMIC COMPANIES
14.6.4 STARTING BLOCKS
14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
14.6.5.1 Detailed list of key startups/SMEs
14.6.5.2 Competitive benchmarking of key startups/SMEs
14.7 COMPANY VALUATION & FINANCIAL METRICS
14.7.1 FINANCIAL METRICS
14.7.2 COMPANY VALUATION
14.8 BRAND/PRODUCT COMPARISON
14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
14.9 COMPETITIVE SCENARIO
14.9.1 DEALS

15 COMPANY PROFILES
15.1 KEY PLAYERS
15.1.1 NEW ENGLAND BIOLABS
15.1.1.1 Business overview
15.1.1.2 Products offered
15.1.1.3 MnM view
15.1.1.3.1 Key strengths
15.1.1.3.2 Strategic choices
15.1.1.3.3 Weaknesses & competitive threats
15.1.2 THERMO FISHER SCIENTIFIC INC.
15.1.2.1 Business overview
15.1.2.2 Products offered
15.1.2.3 MnM view
15.1.2.3.1 Key strengths
15.1.2.3.2 Strategic choices
15.1.2.3.3 Weaknesses & competitive threats
15.1.3 QIAGEN N.V.
15.1.3.1 Business overview
15.1.3.2 Products offered
15.1.3.3 MnM view
15.1.3.3.1 Key strengths
15.1.3.3.2 Strategic choices
15.1.3.3.3 Weaknesses & competitive threats
15.1.4 PROMEGA CORPORATION
15.1.4.1 Business overview
15.1.4.2 Products offered
15.1.4.3 MnM view
15.1.4.3.1 Key strengths
15.1.4.3.2 Strategic choices
15.1.4.3.3 Weaknesses & competitive threats
15.1.5 TAKARA BIO INC.
15.1.5.1 Business overview
15.1.5.2 Products offered
15.1.5.3 MnM view
15.1.5.3.1 Key strengths
15.1.5.3.2 Strategic choices
15.1.5.3.3 Weaknesses & competitive threats
15.1.6 DANAHER CORPORATION
15.1.6.1 Business overview
15.1.6.2 Products offered
15.1.6.3 MnM view
15.1.6.3.1 Key strengths
15.1.6.3.2 Strategic choices
15.1.6.3.3 Weaknesses & competitive threats
15.1.7 AGILENT TECHNOLOGIES, INC.
15.1.7.1 Business overview
15.1.7.2 Products offered
15.1.8 F. HOFFMANN-LA ROCHE LTD.
15.1.8.1 Business overview
15.1.8.2 Products offered
15.1.8.3 Recent developments
15.1.8.3.1 Deals
15.1.9 MERCK KGAA
15.1.9.1 Business overview
15.1.9.2 Products offered
15.1.10 ARCTICZYMES TECHNOLOGIES
15.1.10.1 Business overview
15.1.10.2 Products offered
15.1.11 BIOSYNTH
15.1.11.1 Business overview
15.1.11.2 Products offered
15.1.12 HIMEDIA LABORATORIES
15.1.12.1 Business overview
15.1.12.2 Products offered
15.1.13 LGC BIOSEARCH TECHNOLOGIES
15.1.13.1 Business overview
15.1.13.2 Products offered
15.1.14 INSPIRALIS LIMITED
15.1.14.1 Business overview
15.1.14.2 Products offered
15.1.15 BIONEER CORPORATION
15.1.15.1 Business overview
15.1.15.2 Products offered
15.2 OTHER PLAYERS
15.2.1 GENO TECHNOLOGY INC.
15.2.2 MBR, INC.
15.2.3 ABCLONAL, INC.
15.2.4 NZYTECH
15.2.5 JENA BIOSCIENCE GMBH
15.2.6 CREATIVE ENZYMES.
15.2.7 ENZYNOMICS CO., LTD.
15.2.8 BIOCAT GMBH
15.2.9 GENAXXON BIOSCIENCE
15.2.10 MERIDIAN BIOSICENCE
15.2.11 CANVAX
15.2.12 BIOTECHRABBIT
15.2.13 MCLAB

16 APPENDIX
16.1 DISCUSSION GUIDE
16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
16.3 CUSTOMIZATION OPTIONS
16.4 RELATED REPORTS
16.5 AUTHOR DETAILS